These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 18937801

  • 1. Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration.
    Krebs I, Lie S, Stolba U, Zeiler F, Felke S, Binder S.
    Acta Ophthalmol; 2009 Sep; 87(6):611-7. PubMed ID: 18937801
    [Abstract] [Full Text] [Related]

  • 2. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G.
    Retina; 2006 Sep; 26(5):495-511. PubMed ID: 16770255
    [Abstract] [Full Text] [Related]

  • 3. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ.
    Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
    [Abstract] [Full Text] [Related]

  • 4. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA, Pan-American Collaborative Retina Study Group.
    Retina; 2008 Mar; 28(10):1387-94. PubMed ID: 18827735
    [Abstract] [Full Text] [Related]

  • 5. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study.
    Weigert G, Michels S, Sacu S, Varga A, Prager F, Geitzenauer W, Schmidt-Erfurth U.
    Br J Ophthalmol; 2008 Mar; 92(3):356-60. PubMed ID: 18303156
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.
    Retina; 2007 Mar; 27(4):432-8. PubMed ID: 17420694
    [Abstract] [Full Text] [Related]

  • 8. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K, Sonmez PA, Ozkan SS, Atmaca LS.
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [Abstract] [Full Text] [Related]

  • 9. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
    Arevalo JF, Sánchez JG, Wu L, Berrocal MH, Alezzandrini AA, Restrepo N, Maia M, Farah ME, Brito M, Díaz-Llopis M, Rodríguez FJ, Reategui G, Iturralde-Iraola J, Udaondo-Mirete P, Pan-American Collaborative Retina Study Group.
    Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
    [Abstract] [Full Text] [Related]

  • 10. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
    Melamud A, Stinnett S, Fekrat S.
    Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
    [Abstract] [Full Text] [Related]

  • 11. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
    Leydolt C, Michels S, Prager F, Garhoefer G, Georgopoulos M, Polak K, Schmidt-Erfurth U.
    Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
    [Abstract] [Full Text] [Related]

  • 12. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, Kampik A, Haritoglou C.
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [Abstract] [Full Text] [Related]

  • 13. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
    Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN.
    Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
    [Abstract] [Full Text] [Related]

  • 14. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.
    Stifter E, Michels S, Prager F, Georgopoulos M, Polak K, Hirn C, Schmidt-Erfurth U.
    Am J Ophthalmol; 2007 Dec; 144(6):886-892. PubMed ID: 17916314
    [Abstract] [Full Text] [Related]

  • 15. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
    Algvere PV, Steén B, Seregard S, Kvanta A.
    Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
    [Abstract] [Full Text] [Related]

  • 16. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.
    Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS.
    Ophthalmology; 2005 Jun; 112(6):1035-47. PubMed ID: 15936441
    [Abstract] [Full Text] [Related]

  • 17. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.
    Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA, Scott IU.
    Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4569-78. PubMed ID: 17003454
    [Abstract] [Full Text] [Related]

  • 18. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
    Spaide RF, Laud K, Fine HF, Klancnik JM, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ.
    Retina; 2006 Apr; 26(4):383-90. PubMed ID: 16603955
    [Abstract] [Full Text] [Related]

  • 19. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
    Ahmadieh H, Taei R, Soheilian M, Riazi-Esfahani M, Karkhaneh R, Lashay A, Azarmina M, Dehghan MH, Moradian S.
    BMC Ophthalmol; 2007 Jun 07; 7():10. PubMed ID: 17555600
    [Abstract] [Full Text] [Related]

  • 20. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results.
    Carneiro AM, Falcão MS, Brandão EM, Falcão-Reis FM.
    Retina; 2010 Jan 07; 30(1):85-92. PubMed ID: 20010320
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.